{"id":429,"date":"2012-06-01T00:00:01","date_gmt":"2012-06-01T00:00:01","guid":{"rendered":"https:\/\/awge.doctime.es\/?p=429"},"modified":"2016-05-24T08:04:38","modified_gmt":"2016-05-24T06:04:38","slug":"awge-11","status":"publish","type":"post","link":"https:\/\/awge.doctime.es\/index.php\/2012\/06\/01\/awge-11\/","title":{"rendered":"Transfusion thresholds and other strategies for guidingallogeneic red blood cell transfusion"},"content":{"rendered":"<p>Cochrane Database<br \/>\nJeffrey L Carson1, Paul A Carless2, Paul C Hebert3<br \/>\n<a target=\"_blank\">Acceso al enlace publicador<\/a><\/p>\n<p>Background<br \/>\nMost clinical practice guidelines recommend restrictive red cell transfusion practices, with the goal of minimising exposure to allogeneic<br \/>\nblood. The purpose of this review is to compare clinical outcomes in patients randomised to restrictive versus liberal transfusion<br \/>\nthresholds (triggers).<br \/>\nObjectives<br \/>\nTo examine the evidence for the effect of transfusion thresholds on the use of allogeneic and\/or autologous red cell transfusion, and the<br \/>\nevidence for any effect on clinical outcomes.<br \/>\nSearch methods<br \/>\nWe identified trials by searching: the Cochrane Injuries Group Specialised Register (searched 1 February 2011), the Cochrane Central<br \/>\nRegister of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 1), MEDLINE (Ovid) 1948 to January Week 3 2011,<br \/>\nEMBASE (Ovid) 1980 to 2011 (Week 04), ISIWeb of Science: Science Citation Index Expanded (1970 to February 2011) and ISIWeb<br \/>\nof Science: Conference Proceedings Citation Index &#8211; Science (1990 to February 2011). We checked reference lists of other published<br \/>\nreviews and relevant papers to identify any additional trials.<br \/>\nSelection criteria<br \/>\nControlled trials inwhich patientswere randomised to an intervention group or to a control group.We included trialswhere intervention<br \/>\ngroups were assigned on the basis of a clear transfusion \u2019trigger\u2019, described as a haemoglobin (Hb) or haematocrit (Hct) level below<br \/>\nwhich a red blood cell (RBC) transfusion was to be administered.<br \/>\nData collection and analysis<br \/>\nWe pooled risk ratios of requiring allogeneic blood transfusion, transfused blood volumes and other clinical outcomes across trials using<br \/>\na random-effects model. Two people performed data extraction and assessment of the risk of bias.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cochrane Database Jeffrey L Carson1, Paul A Carless2, Paul C Hebert3 Acceso al enlace publicador Background Most clinical practice guidelines<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/429"}],"collection":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/comments?post=429"}],"version-history":[{"count":1,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/429\/revisions"}],"predecessor-version":[{"id":626,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/429\/revisions\/626"}],"wp:attachment":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/media?parent=429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/categories?post=429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/tags?post=429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}